Should I buy or sell Forte Biosciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FBRX shares. View FBRX analyst ratings or view top-rated stocks .

What is Forte Biosciences' stock price target for 2024?

2 equities research analysts have issued twelve-month price targets for Forte Biosciences' shares. Their FBRX share price targets range from $2.75 to $2.75. On average, they predict the company's share price to reach $2.75 in the next year. This suggests a possible upside of 252.6% from the stock's current price. View analysts price targets for FBRX or view top-rated stocks among Wall Street analysts .

How have FBRX shares performed in 2024?

Forte Biosciences' stock was trading at $0.8217 at the beginning of 2024. Since then, FBRX stock has decreased by 5.1% and is now trading at $0.78. View the best growth stocks for 2024 here .

Are investors shorting Forte Biosciences?

Forte Biosciences saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 34,100 shares, a decrease of 19.2% from the March 15th total of 42,200 shares. Based on an average daily volume of 34,300 shares, the days-to-cover ratio is currently 1.0 days. View Forte Biosciences' Short Interest .

When is Forte Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FBRX earnings forecast .

How were Forte Biosciences' earnings last quarter?

Forte Biosciences, Inc. (NASDAQ:FBRX) issued its earnings results on Monday, March, 18th. The company reported ($0.04) EPS for the quarter.

What other stocks do shareholders of Forte Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN) , Chimerix (CMRX) , electroCore (ECOR) , Great Panther Mining (GPL) , Immunic (IMUX) , Infinera (INFN) and Stride (LRN) .

How do I buy shares of Forte Biosciences?

Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FBRX

Forte Biosciences (FBRX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free FBRX Stock Alerts

$0.78

+0.04 (+5.41%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.73
▼
$0.78
50-Day Range: $0.62
▼
$0.78
52-Week Range: $0.38
▼
$1.15

Volume: 57,449 shs
Average Volume: 24,756 shs
Market Capitalization: $28.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.75

Get Forte Biosciences alerts:

Forte Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 252.6% Upside
$2.75 Price Target
Short Interest: Healthy
0.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.32
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.46) to ($0.45) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.39 out of 5 stars

Medical Sector

255th out of 918 stocks

Pharmaceutical Preparations Industry

106th out of 430 stocks

3.3

Analyst's Opinion

Consensus Rating
Forte Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Forte Biosciences has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.09% of the outstanding shares of Forte Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Forte Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Forte Biosciences has recently decreased by 19.19%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Forte Biosciences does not currently pay a dividend.
Dividend Growth
Forte Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FBRX.

3.0

News and Social Media Coverage

News Sentiment
Forte Biosciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Forte Biosciences this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for FBRX on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Forte Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Forte Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.53% of the stock of Forte Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Forte Biosciences are expected to grow in the coming year, from ($0.46) to ($0.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Forte Biosciences is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Forte Biosciences is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Forte Biosciences has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Forte Biosciences Stock (NASDAQ:FBRX)

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

FBRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FBRX Stock News Headlines

April 18, 2024 | americanbankingnews.com

Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)

April 10, 2024 | benzinga.com

Forte Biosciences Stock (NASDAQ:FBRX), Analyst Ratings, Price Targets, Predictions

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | americanbankingnews.com

LADENBURG THALM/SH SH Upgrades Forte Biosciences (NASDAQ:FBRX) to Buy

April 8, 2024 | markets.businessinsider.com

Buy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market Position

March 19, 2024 | investorplace.com

FBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023

March 18, 2024 | businesswire.com

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

December 12, 2023 | morningstar.com

Forte Biosciences Inc Ordinary Shares

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

December 9, 2023 | finance.yahoo.com

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

November 15, 2023 | morningstar.com

Forte Biosciences Inc Ordinary Shares FBRX

November 14, 2023 | msn.com

Forte Biosciences GAAP EPS of -$0.26

November 13, 2023 | finance.yahoo.com

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

September 14, 2023 | benzinga.com

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

September 14, 2023 | finance.yahoo.com

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual Meeting

September 6, 2023 | finance.yahoo.com

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s Boardroom

August 25, 2023 | businesswire.com

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

August 25, 2023 | 247wallst.com

Camac Fund Now Owns 4.3% of Forte Biosciences

August 14, 2023 | finance.yahoo.com

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

August 3, 2023 | benzinga.com

Chief Financial Officer At This Health Care Company Buys $149K of Stock

August 1, 2023 | finance.yahoo.com

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

July 4, 2023 | finance.yahoo.com

This Forte Biosciences Insider Increased Their Holding In The Last Year

May 24, 2023 | finance.yahoo.com

We're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

May 19, 2023 | finance.yahoo.com

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

May 15, 2023 | finance.yahoo.com

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

April 6, 2023 | msn.com

Unusual Call Option Trade in Forte Biosciences (FBRX) Worth $2.50K

March 31, 2023 | finance.yahoo.com

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

See More Headlines

Receive FBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:FBRX
CUSIP: N/A
CIK: 1419041
Web: www.fortebiorx.com
Phone: (310) 618-6994
Fax: N/A
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.75
High Stock Price Target: $2.75
Low Stock Price Target: $2.75
Potential Upside/Downside: +252.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,480,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -94.27%
Return on Assets: -81.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.45
Quick Ratio: 10.45

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.97 per share
Price / Book: 0.80

Miscellaneous

Outstanding Shares: 36,400,000
Free Float: 32,563,000
Market Cap: $28.39 million
Optionable: Optionable
Beta: 0.48

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Paul A. Wagner Ph.D. (Age 54)
CEO, President & Chairman
Comp: $914.5k
Mr. Antony A. Riley CPA (Age 57)
Chief Financial Officer
Comp: $532k
Mr. Christopher Roenfeldt
Chief Operating Officer
Mr. Steven Ruhl (Age 67)
Chief Technical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FBRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Forte Biosciences stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FBRX shares.
View FBRX analyst ratings or view top-rated stocks.
What is Forte Biosciences' stock price target for 2024?: 2 equities research analysts have issued twelve-month price targets for Forte Biosciences' shares. Their FBRX share price targets range from $2.75 to $2.75. On average, they predict the company's share price to reach $2.75 in the next year. This suggests a possible upside of 252.6% from the stock's current price.
View analysts price targets for FBRX or view top-rated stocks among Wall Street analysts.
How have FBRX shares performed in 2024?: Forte Biosciences' stock was trading at $0.8217 at the beginning of 2024. Since then, FBRX stock has decreased by 5.1% and is now trading at $0.78.
View the best growth stocks for 2024 here.
Are investors shorting Forte Biosciences?: Forte Biosciences saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 34,100 shares, a decrease of 19.2% from the March 15th total of 42,200 shares. Based on an average daily volume of 34,300 shares, the days-to-cover ratio is currently 1.0 days.
View Forte Biosciences' Short Interest.

When is Forte Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our FBRX earnings forecast.
How were Forte Biosciences' earnings last quarter?: Forte Biosciences, Inc. (NASDAQ:FBRX) issued its earnings results on Monday, March, 18th. The company reported ($0.04) EPS for the quarter.
What other stocks do shareholders of Forte Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Chimerix (CMRX), electroCore (ECOR), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN).
How do I buy shares of Forte Biosciences?: Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FBRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Forte Biosciences (FBRX) Stock Price, News & Analysis

Forte Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Forte Biosciences Stock (NASDAQ:FBRX)

FBRX Stock Price History

FBRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

FBRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™